He could’ve died!
It’s amazing he didn’t.
A couple weeks ago, 10-year-old Luca Ingrassia had a near-fatal allergy attack after eating a cashew on an American Airlines flight.
Had it not been for a fellow passenger’s EpiPen and a quick-thinking nurse who happened to be on board, Luca would’ve lost his life.
It’s crazy how many kids are allergic to all kinds of different foods today.
And many of these allergies are life threatening.
But thanks to a new technology — which is only being tested by a few companies — the days of life-threatening food allergies may soon come to an end.
And rest assured, dear reader, the companies behind this technology are going to make billions.
That’s why we’re investing in them now — before the dolts on Wall Street figure out just how huge of an opportunity this is.
The Holy Grail of Modern Medicine
It’s called CRISPR, and it’s a specialized gene-editing technology that literally deletes ailments and diseases from your genetic code.
While early studies have suggested CRISPR could be used to end the scourge of fatal food allergies, it could also be used to treat…
- Heart disease
- Cancer
- Diabetes
- Alzheimer’s
- HIV
- Hepatitis
And 6,000 other genetic disorders.
Think about that for a second…
Think about the hundreds of billions of dollars that are spent every year to treat all of these illnesses.
Now imagine that just a small handful of companies have the ability to swoop in, end these diseases forever, and take billions of dollars’ worth of market share from the big pharmaceutical companies.
Our analysts have traveled the world over, dedicated to finding the best and most profitable investments in the global energy markets. All you have to do to join our Energy and Capital investment community is sign up for the daily newsletter below.
Well, you don’t actually have to imagine it, because it’s very, very real.
Truth is, that small group of companies is now being called “the New Big Pharma” because it’s about to take over where Big Pharma has failed: completely wiping out nearly every fatal disease on Earth, instead of just treating the symptoms until the disease ultimately wins.
My friend, this is no longer the stuff of science fiction. This IS the new generation of medicine.
And we’re about to make a fortune by investing in the companies that are making all this happen.
Of course, we’re not the only ones.
Bill Gates has skin in the game after ponying up $35 million to get a piece of this action.
Sean Parker from Facebook has part of his $250 million “Solve Cancer” fund committed to CRISPR, and Mark Zuckerberg has put up $50 million.
These guys don’t invest in things that lose.
And they’re incredibly bullish on CRISPR.
You should be, too.
Because, quite frankly, this is the kind of stuff that turns average investors into millionaires.
Truly disruptive technologies have a way of doing this.
We saw it in the early telecom days, we saw it in the early days of the internet, and we’re about to see it again in what is, quite frankly, the Holy Grail of modern medicine.
Science magazine called it “the breakthrough of the year.”
CNN says, “It’ll spare millions from pain and suffering.”
Bloomberg called it “The Discovery of the Century.”
But I’m calling it what it is…
The greatest opportunity we’ll ever have to turn small amounts of cash into huge fortunes.
And that’s why I wrote a new report that not only explains the technology in detail, but also includes the four most influential companies (and their ticker symbols) turning this medical miracle into reality.
You can access this report by clicking this link.
The report is called “The End of Disease: The Last Investment You’ll Ever Need to Make.”
And I’m happy to share it with you today.
Just click this link, and you’ll see why MIT has just called this technology the “Biggest Biotech Discovery of the Century.”
Even if you’re not sure about investing in this technology, I strongly urge you to read about it, as it could one day actually save your life.
It’s just that important.
To a new way of life and a new generation of wealth…
Jeff Siegel
Check us out on YouTube!
@JeffSiegel on Twitter
Jeff is the founder and managing editor of Green Chip Stocks. For more on Jeff, go to his editor’s page.
Want to hear more from Jeff? Sign up to receive emails directly from him ranging from market commentaries to opportunities that he has his eye on.
